Clinical Trial

Impact of Beta Blockers on TAVI (BETA-TAVI)

Study acronym: BETA-TAVI
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This is a prospective, multicentre, investigator-initiated, randomized clinical trial clinical trial investigating the impact of beta-blockers administration among patients undergoing TAVI for severe aortic valve stenosis. Adults already receiving beta-blockers be assigned randomly in 1:1 ratio to either continue or withdraw the beta-blockers medication at least 72 hours before and at least 7 days after TAVI. The primary endpoint is permanent pacemaker implantation rates in 7 days after the procedure. Secondary endpoints include death, cardiogenic shock and arrhythmias/conduction abmormalities with time frame 12 months.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-01-31; most recent amendment 2024-12-04.
Status change: Not Yet Recruiting → Recruiting 2024-12-04
Trial Details
NCT Number NCT05721170
Lead Sponsor National and Kapodistrian University of Athens
Conditions Aortic Valve Stenosis
Enrollment 347 participants
Start Date 2024-06-01
Primary Completion 2028-01-30 (estimated)
Study Completion 2028-01-31 (estimated)
Updated on ClinicalTrials.gov 2024-12-09